You are now leaving Abacavir HSR Support. ViiV/GSK do not recommend, endorse or accept liability for sites controlled by third parties.
Patients must be made aware of the possibility of a hypersensitivity reaction to abacavir that may result in a life-threatening reaction or death and that the risk of a hypersensitivity reaction is increased if they are HLA-B*5701 positive.
The below guidelines can be used by the healthcare professional to conduct the conversation with the patient (or parents and guardians of children).
Have a plan to communicate in the event of a reaction
Each patient should be reminded to read the Package Leaflet included in the abacavir pack. They should be reminded of the importance of removing the Alert Card included in the pack, and keeping it with them at all times.
In order to avoid restarting abacavir, patients who have experienced a hypersensitivity reaction should be asked to return the remaining abacavir tablets or oral solution to the pharmacy.
* ViiV Healthcare does not recommend, endorse or accept liability for sites controlled by third parties.